Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9157699 | 0.88 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL442715 | 0.88 | P2RY14 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL2112756 | 0.86 | TK1 (0.37) | P2RY6 | |
| SCHEMBL2115511 | 0.85 | PYGM (0.43) | P2RY2P2RY14P2RY6 | |
| SCHEMBL2114241 | 0.85 | PYGM (0.43) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6328518 | 0.84 | DUT (0.50) | — | |
| SCHEMBL5150767 | 0.82 | NT5E (0.49) | — | |
| SCHEMBL443437 | 0.81 | DUT (0.35) | P2RY2P2RY4P2RY6 | |
| SCHEMBL8970268 | 0.81 | P2RY14 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL8538694 | 0.81 | P2RY14 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117980497-A | Systems, methods, and compositions for detecting epigenetic modifications of nucleic acids | X基因组公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4320268-A2 | SYSTEMS, METHODS, AND COMPOSITIONS FOR DETECTING EPIGENETIC MODIFICATIONS OF NUCLEIC ACIDS | XGenomes Corp. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230193258-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2023-06-22 | — | — | US | disclosed |
| US-11208654-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2021-12-28 | — | — | US | disclosed |
| CN-112955568-A | Compositions and methods for improved library enrichment | ILLUMINA公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20200032255-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | CITY OF HOPE | 2020-01-30 | — | — | US | disclosed |
| US-10253318-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2019-04-09 | — | — | US | disclosed |
| US-9688982-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2017-06-27 | — | — | US | disclosed |
| US-9200279-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200280-B2 | Methods and compositions for the treatment of cancer or other diseases | CITY OF HOPE (US) | 2015-12-01 | — | — | US | disclosed |
| US-5886193-A | COUPLING TO A SUPPORT CARRIERS | ZENECA LIMITED (GB) | 1999-03-23 | — | — | US | disclosed |
| EP-0405913-B1 | Hydrophobic nucleic acid probe | CHIRON CORP (US) | 1998-12-23 | — | — | EP | disclosed |
| EP-0633890-B1 | SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | ZENECA LTD (GB) | 1998-09-09 | — | — | EP | disclosed |
| US-5702893-A | BINDING TARGET POLYNUCLEOTIDE IN SAMPLE USING AS ASSAY REAGENT SUBSTRATE HAVING POLYNUCLEOTIDE CAPTURE PROBE BOUND THERETO BY HYDROPHOBIC MOIETY, HYBRIDIZING | CHIRON CORPORATION (US) | 1997-12-30 | — | — | US | disclosed |
| US-5681945-A | SUPPORT COUPLED TO COMPOUND CONTAINING CARBO- OR HETEROCYCLIC RING HAVING FIRST CARBON SUBSTITUTED BY NUCLEOPHILIC GROUP AND SECOND CARBON BY (PROTECTED)HYDROXY OR SUBSTITUTED PHOSPHATE GROUP, FOR OLIGONUCLEOTIDE SYNTHESIS | ZENECA LIMITED (GB) | 1997-10-28 | — | — | US | disclosed |
| US-5552280-A | Hydrophobic nucleic acid probes | CHIRON CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0633890-A1 | SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | ZENECA LIMITED (GB) | 1995-01-18 | — | — | EP | disclosed |
| WO-1993020091-A1 | SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | ZENECA LIMITED (GB) | 1993-10-14 | — | — | WO | disclosed |
| WO-1991000288-A1 | HYDROPHOBIC NUCLEIC ACID PROBE | CHIRON CORP (US) | 1991-01-10 | — | — | WO | disclosed |
| EP-0405913-A2 | Hydrophobic nucleic acid probe | CHIRON CORPORATION (US) | 1991-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208654-B2 | Methods and compositions for the treatment of cancer or other diseases | HLA-DRB1, CD47, IL2 | SLC28A1 2588/4885SLC28A2 2578/4885SLC29A1 2679/4885 |
| US-20200032255-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | SLC28A1 2588/4885SLC28A2 2578/4885SLC29A1 2679/4885 |
| US-20230193258-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES | HLA-DRB1, CD47, IL2 | SLC28A1 2588/4885SLC28A2 2578/4885SLC29A1 2679/4885 |
| US-10253318-B2 | Methods and compositions for the treatment of cancer or other diseases | HLA-DRB1, CD47, IL2 | SLC28A1 2588/4885SLC28A2 2578/4885SLC29A1 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.